Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director · Executive Chair | November 07, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 25,873 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 25,873 · Balance 25,873 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date November 07, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,422.063 |
Reported balance
After 2022-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-07 · Exercise / conversion · Acquired 235,769 · Balance 936,422.063 |
| Common StockSEC Table I · non-derivative | Direct | 911,508.063 |
Reported balance
After 2022-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-07 · Sale · Disposed 24,914 · Balance 911,508.063 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 785,374.063 |
Reported balance
After 2022-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-07 · Sale · Disposed 126,134 · Balance 785,374.063 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 700,653.063 |
Reported balance
After 2022-11-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-07 · Sale · Disposed 84,721 · Balance 700,653.063 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4: Holdings include shares acquired in dividend reinvestment transactions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.06 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2022-11-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-07 · Exercise / conversion · Disposed 235,769 · Balance 0 F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 4,481.1286 |
Reported balance
Holding disclosure · report date 2022-11-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,481.1286 F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXXON MOBIL CORP
Report date May 25, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2020 Filed Nov 12, 2020 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 135,134 | $81.08 | $10,956,070.13 |
DisclosureSEC source: 0001127602-20-028825 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,412.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.41 to $81.39, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| October 30, 2020 Filed Feb 9, 2021 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 64,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004702 · form5.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,546.063 F1 · balance_after: Amount reported reflects the number of shares beneficially owned at the end of fiscal year 2020, taking into account all transactions reported here and the sale transactions reported on Form 4 filed on November 12, 2020. Read SEC document |
| September 17, 2020 Filed Feb 9, 2021 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004702 · form5.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,546.063 F1 · balance_after: Amount reported reflects the number of shares beneficially owned at the end of fiscal year 2020, taking into account all transactions reported here and the sale transactions reported on Form 4 filed on November 12, 2020. Read SEC document |
| August 25, 2020 Filed Feb 9, 2021 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004702 · form5.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,546.063 F1 · balance_after: Amount reported reflects the number of shares beneficially owned at the end of fiscal year 2020, taking into account all transactions reported here and the sale transactions reported on Form 4 filed on November 12, 2020. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 475,740 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001127602-20-015449 · form4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,740 Underlying: Common Stock · 475,740 shares Expires 2030-04-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 119,291 | $76.56 | $9,132,918.96 |
DisclosureSEC source: 0001127602-20-009146 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,619.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:11 UTC | EXXON MOBIL CORP XOM · Entity 32533 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-000644 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 F1 · price: Restricted stock grant. Read SEC document |
| November 12, 2019 Filed Feb 13, 2020 22:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 118,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005334 · form5.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,328.063 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 06, 2019 Filed May 9, 2019 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 14,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028306 · a4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,092.063 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 423,402 | $0.00 Strike: $80.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027581 · a4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,402 Underlying: Common Stock · 423,402 shares Expires 2029-05-02 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| March 20, 2019 Filed Mar 20, 2019 22:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 192,736 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-005629 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,736 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| March 20, 2019 Filed Mar 20, 2019 22:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 192,736 | $82.05 | $15,813,372.04 |
DisclosureSEC source: 0001225208-19-005629 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,715.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.0000 to $82.1900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 20, 2019 Filed Mar 20, 2019 22:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 192,736 | $39.29 | $7,572,597.44 |
DisclosureSEC source: 0001225208-19-005629 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 990,451.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 22:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 18,725 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-005291 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,736 Underlying: Common Stock · 18,725 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 22:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 18,725 | $82.00 | $1,535,453.75 |
DisclosureSEC source: 0001225208-19-005291 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,715.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.0000 to $82.0050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 22:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 18,725 | $39.29 | $735,705.25 |
DisclosureSEC source: 0001225208-19-005291 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,440.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 23:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 6,961 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-004825 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,461 Underlying: Common Stock · 6,961 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 23:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 6,961 | $82.00 | $570,808.96 |
DisclosureSEC source: 0001225208-19-004825 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,715.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.0000 to $82.0150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 23:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,961 | $39.29 | $273,497.69 |
DisclosureSEC source: 0001225208-19-004825 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,676.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 13,144 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-004825 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,422 Underlying: Common Stock · 13,144 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 13,144 | $82.01 | $1,077,875.03 |
DisclosureSEC source: 0001225208-19-004825 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,715.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.0000 to $82.0400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 13,144 | $39.29 | $516,427.76 |
DisclosureSEC source: 0001225208-19-004825 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,859.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 105,765 | $80.38 | $8,501,390.70 |
DisclosureSEC source: 0001225208-19-003893 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,715.063 F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 22, 2019 Filed Feb 22, 2019 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 53,961 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-003408 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,566 Underlying: Common Stock · 53,961 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 22, 2019 Filed Feb 22, 2019 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 53,961 | $80.02 | $4,318,088.73 |
DisclosureSEC source: 0001225208-19-003408 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 22, 2019 Filed Feb 22, 2019 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 53,961 | $39.29 | $2,120,127.69 |
DisclosureSEC source: 0001225208-19-003408 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,911.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 41,992 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-003408 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,527 Underlying: Common Stock · 41,992 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 41,992 | $80.00 | $3,359,452.38 |
DisclosureSEC source: 0001225208-19-003408 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 41,992 | $39.29 | $1,649,865.68 |
DisclosureSEC source: 0001225208-19-003408 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,942.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 22:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 42,700 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-002960 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,519 Underlying: Common Stock · 42,700 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 22:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 42,700 | $80.02 | $3,416,943.67 |
DisclosureSEC source: 0001225208-19-002960 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 22:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 42,700 | $39.29 | $1,677,683.00 |
DisclosureSEC source: 0001225208-19-002960 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,650.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 92,913 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-002960 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,219 Underlying: Common Stock · 92,913 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 92,913 | $80.03 | $7,436,161.88 |
DisclosureSEC source: 0001225208-19-002960 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.1300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 92,913 | $39.29 | $3,650,551.77 |
DisclosureSEC source: 0001225208-19-002960 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,863.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 231,566 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-001889 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,132 Underlying: Common Stock · 231,566 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 231,566 | $78.08 | $18,079,654.39 |
DisclosureSEC source: 0001225208-19-001889 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.0000 to $78.3700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 231,566 | $39.29 | $9,098,228.14 |
DisclosureSEC source: 0001225208-19-001889 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,516.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 15:43 UTC | EXXON MOBIL CORP XOM · Entity 32533 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001052 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · price: Restricted stock grant. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 279,850 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-014342 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 279,850 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 279,850 | $72.07 | $20,168,257.79 |
DisclosureSEC source: 0001225208-18-014342 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.17, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 279,850 | $36.56 | $10,231,316.00 |
DisclosureSEC source: 0001225208-18-014342 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,800.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 279,851 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-013571 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,850 Underlying: Common Stock · 279,851 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 279,851 | $70.08 | $19,611,818.15 |
DisclosureSEC source: 0001225208-18-013571 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.0000 to $70.4200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 279,851 | $36.56 | $10,231,352.56 |
DisclosureSEC source: 0001225208-18-013571 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,801.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 228,091 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 228,091 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 18,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 228,091 | $65.00 | $14,826,690.51 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,697.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.05, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 228,091 | $33.49 | $7,638,767.59 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,788.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 475,743 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008935 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,743 Underlying: Common Stock · 475,743 shares Expires 2028-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.